The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
Open Access
- 3 April 2013
- Vol. 3 (4), e002560
- https://doi.org/10.1136/bmjopen-2013-002560
Abstract
Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial for routine diagnostics. Till date these data have been derived mostly from clinical trials, and thus collected in pre-selected populations. We therefore screened ‘allcomers’ with a newly diagnosed non-small cell lung carcinoma (NSCLC) for the frequencies of these mutations. Design A cohort study. Setting Lung cancer centre in a tertiary care hospital. Participants Within 15 months, a total of 552 cases with NSCLC were eligible for analysis. Primary and secondary outcome measures Frequency of scrutinising exons 18, 19 and 21 for the presence of activating EGFR mutation and secondary codon 12 and 13 for activating KRAS mutations. Results Of the 552 patients, 27 (4.9%) showed a mutation of EGFR. 19 of these patients (70%) had deletion E746-A750 in codon 19 or deletion L858R in codon 21. Adenocarcinoma (ACA) was the most frequent histology among patients with EGFR mutations (ACA, 22/254 (8.7%) vs non-ACA, 5/298 (1.7%); pConclusions We found a lower frequency for EGFR and KRAS mutations in an unselected Caucasian patient cohort as previously published. Taking our results into account, clinical trials may overestimate the mutation frequency for EGFR and KRAS in NSCLC due to important selection biases.This publication has 33 references indexed in Scilit:
- Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohortEuropean Respiratory Journal, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysisEnvironmental and Molecular Mutagenesis, 2011
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African AmericansJournal of Thoracic Oncology, 2011
- Smoking prevalence in the European Union: a comparison of national and transnational prevalence survey methods and resultsTobacco Control, 2010
- The status of KRAS mutations in patients with non-small cell lung cancers from mainland ChinaOncology Reports, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancerAnnals of Oncology, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004